Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

NGM - NGM BIOPHARMACEUTICALS INC

Close
1.55
1.550   100.000%

Share volume: 0
Last Updated: Thu 04 Apr 2024 08:16:47 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.45%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
29%
Profitability 25%
Dept financing 12%
Liquidity 75%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
71.30%
2 Year
-67.98%
Key data
Stock price
$1.55
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$1.73
52 WEEK RANGE
$0.96 - $2.20
52 WEEK CHANGE
$71.11
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
83.462 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: David J. Woodhouse
Region: US
Website: ngmbio.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

NGM Biopharmaceuticals, Inc. engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. Its product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH)

Recent news